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A B S T R A C T
Background: Postural stability analysis has shown that postural control is impaired in untreated
idiopathic Parkinson’s disease (IPD), even in the early stages of the disease. Vascular Parkinson’s disease
(VPD) lacks consensus clinical criteria or diagnostic tests. Moreover, the levodopa effect on postural
balance remains undeﬁned for IPD and even less so for VPD.
Objective: To characterize postural stability, using kinematic analysis with wearable inertial
measurement units, in IPD and VPD patients without clinical PI, and to subsequently analyze the
response to levodopa.
Methods: Ten patients with akinetic-rigid IPD and ﬁve patients with VPD were included. Clinical and
postural stability kinematic analysis was performed before and after levodopa challenge, on different
standing tasks: normal stance (NS), Romberg eyes open (REO) and Romberg eyes closed.
Results: In the ‘‘off state’’, VPD patients had higher mean distances and higher maximal distance of
postural sway on NS and REO tasks, respectively. VPD patients maintained a higher range of anterior–
posterior (AP) postural sway after levodopa. In the absence of PI and non-signiﬁcant differences in
UPDRS-III, a higher mPIGD score in the VPD patients was mainly due to gait disturbance. Gait
disturbance, and not UPDRS-III, inﬂuenced the degree of postural sway response to levodopa for VPD
patients.
Conclusion: Quantitative postural sway evaluation is useful in the investigation of Parkinsonian
syndromes. VPD patients have higher AP postural sway that is correlated with their gait disturbance
burden and also not responsive to levodopa. These observations corroborate the interconnection of
postural control and locomotor networks.
 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Postural control encompasses the acts of aligning the body with
respect to gravity and maintaining, achieving or restoring the body
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3.0/).generally, within the limits of stability during daily activities.
Postural control is achieved by the complex integration and
coordination of multiple body systems, including the vestibular,
visual, auditory, motor, and higher level premotor systems [1],
often unconsciously [2]. Postural instability (PI) is one of the most
disabling features of idiopathic Parkinson’s disease (IPD) and,
generally, it is a manifestation of the late stages of the disease
[3]. Yet, there is some evidence that postural control is already
impaired in early stage of IPD without overt clinical PI [4]. Postural
control can be characterized by the following four main postural
control systems: (1) balance during quiet stance, (2) reactivee under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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postural adjustments in preparation for voluntary movements, and
(4) dynamic balance during movements, such as gait [5]. In this
sense, postural control has a fundamental role in gait of
establishing and maintaining appropriate postural orientation of
body segments relative to each another and to the environment as
well as to ensure dynamic stability of the moving body [6].
Vascular Parkinsonism (VPD) is a Parkinsonian syndrome that is
typically characterized by lower body parkinsonism, marked gait
difﬁculty, less tremor, less rigidity, better hand dexterity, relatively
symmetrical symptomatic distribution, association with pyrami-
dal tract signs, more frequent dementia, and poor response to
levodopa treatment compared to IPD [7]. However, there are no
consensus clinical criteria for VPD or its speciﬁc clinical features;
additionally, there is a lack of diagnostic tests to differentiate VPD
from IPD [8]. In terms of treatment, although it is recognized that
the dopaminergic beneﬁt tends to fade away with the progression
of IPD, the objective effect of dopaminergic therapy on postural
balance remains controversial for IPD and is even more question-
able for VPD. There is increasing research to understand what and
how networks of postural control and gait, both dopaminergic and
non-dopaminergic, interact [9]. VPD, which is pathologically
different from Parkinsonian syndrome but with clinical similarities
to IPD [8], may serve as a good comparison model for investigating
the postural stability on different and increasingly demanding
postural and cognitive tasks and its response to levodopa.
Objective measures of balance using wearable inertial sensors
are sensitive, speciﬁc and responsive to postural balance testing on
clinical practice [10] and act as a diagnostic tool that is
complementary to the traditional force plate measurements
[4]. To characterize postural stability in IPD and VPD patients
and to subsequently analyze the response to levodopa, we
evaluated postural stability using kinematic analysis derived from
wearable inertial measurement units on early disease akinetic-
rigid IPD and VPD patients without clinical PI.
2. Materials and methods
2.1. Subjects and clinical assessment
Patients were consecutively recruited from our Movement
Disorders outpatient consult, fulﬁlling criteria for IPD (UKPDS
Brain Bank criteria) or VPD [8]. IPD and VPD patients had normal
clinical postural stability measured by the retropulsion test (item
12 on MDS-UPDRS-III), and they had no dyskinesia. IPD patients
had an Hoehn&Yahr of 2 (‘‘off state’’) and an akinetic-rigid proﬁle.
VPD patients predominantly presented with lower body Parkin-
sonism with independent but impaired gait; they were short
stepped and stooped, which was related to an acute or chronic
cerebrovascular disease, fulﬁlling the proposed criteria for VPD
[8]. VPD patients had subcortical or basal ganglia focal lesions
without large vessels stroke that were qualitatively classiﬁed from
the neuroradiologist’s reports. Patients were considered as being
on their best ‘‘on’’ dopaminergic regimen in the three previous
months. The exclusion criteria were dementia, orthopedic,
musculoskeletal, vestibular disorder, signiﬁcant visual or auditory
deﬁcit, and alcohol abuse. VPD patients with motor deﬁcits,
whether related to stroke or not, were also excluded.
Age has been associated with kinetic performance for postural
stability [11]. Therefore, VPD and IPD age-matched patients were
included. The collected variables consisted of demographic
(gender, age, and education) and biometric data reported as
inﬂuencing kinetic performance, such as weight, height, body mass
index. The center of mass (COM) was determined at 55% of a
patient’s height above the ground [12]. Clinical data were also
collected, including years of disease duration; Movement DisorderSociety-Uniﬁed Parkinson’s Disease Rating Scale III (MDS-UPDRS
III) (scored as either an on ‘‘off’’ or on ‘‘on’’ state); Levodopa
Equivalent Levodopa Daily Dose [13]; Levodopa suprathreshold
challenge dose; and motor beneﬁt (percentage of the difference
between ‘‘off’’ and ‘‘on’’ states). The modiﬁed Postural Instability
Gait Disorder (PIGD) score part III was derived from the sum of
MDS-UPDRS items (3.9 (arising from chair), 3.10 (gait), 3.11
(freezing of gait), 3.12 (postural stability), 3.13 (posture), and 3.14
(global spontaneity of movement)) [14]. A brief neuropsychologi-
cal examination was performed using the Portuguese version of
the Montreal Cognitive Assessment test (MoCA) with scores
normalized to the Portuguese population [15] no more than
1 month prior to the kinetic assessment. The levels of education
were categorized by years of schooling as follows: 0 (analphabetic),
1 (1–4 years), 2 (5–9 years), 3 (10–12 years), and 4 (>12 years). The
study protocol derived from the ICVS-3Bs and the Algoritmi Center
and was approved by hospital local ethics committee. Written
informed consent was received from all participants in the study.
2.2. Kinematic postural tasks
Five kinetic sensing modules, harboring an 8051 microprocessor
embedded in CC2530 Texas Instrument SoC (System on Chip), and a
wearable inertial measurement unit MPU6000 (tri-axial accelerom-
eter and gyroscope) [16] operating with a sample rate frequency of
113 Hz on a SD card were attached to the following ﬁve body
segments: trunk (on the COM); both legs (middle of ankle-knee) and
both thighs (middle of knee-iliac crest) by Velcro bands. Video
capture (sample rate of 60 fps) and data logging were synchronized
by a bidirectional radio signal transmission through a USB coordina-
tor node connected to a PC with custom designed Matlab software.
Our methodology and mathematical formulas for kinematic
acquisition have been previously published [17]. We focused on
some kinematic measurements that were derived from the
wearable sensor unit placed at the COM, including the total
length of sway (cm); maximal and mean distance of sway (cm)
with respect to the origin; maximal linear velocity (cm/s); and
range of medial-lateral (ML) and anterior–posterior (AP) sway (cm)
(on the X and Y axis transverse planes, respectively). As one of the
human’s mechanisms of maintaining balance is to vary the height
and COM by bending the knees and trunk, kinematic data was
constantly adjusted to real height adjusted from the wearable
sensor units placed on the shanks and thighs.
Subjects were instructed to perform the following three
different tasks, ﬁrst in the ‘‘off’’ and then in the ‘‘on state’’: normal
comfortable standing, Romberg test with eyes open, and Romberg
with eyes closed. Patients were clinically and kinematically
evaluated in the ‘‘off state’’, in the morning, after a 12-h period
without any dopaminergic medication. Afterwards, they were
given a suprathreshold dopaminergic medication of 150% of their
usual morning dose and were re-examined 90 min later regardless
of the intensity of their subjective response.
Subjects performed the Romberg test barefoot with the medial
aspects of the feet touching each other. During the tasks, subjects
stood quietly with their arms hanging at their sides and their head in
a normal forward-looking eye position directed to an object placed at
2 m away. All tasks were explained, and subjects had the chance to
train before the deﬁnitive trial. Each task was performed for 30 s;
during that time, the kinematic data were recorded. The trial was
invalidated and started again if subjects moved any part of their body,
spoke, opened their eyes for visual aid or performed a corrective step.
2.3. Statistical analysis
Gender comparisons were analyzed by the x2 Fisher exact test.
Given the small number of subjects, statistical analysis was carried
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(comparison between groups), and by a Wilcoxon matched pair
test for the magnitude of change (intragroup) after levodopa
challenge and for the effect of the visual suppression effect.
Intragroup correlation of the basal (‘‘off state’’) mPIGD score and
the total MDS-UPDRS III score with a change in postural sway
variables after levodopa challenge was evaluated with the
Spearman test. Statistical analyses were conducted with software
(SPSS 20.0) using a 95% level of signiﬁcance.
3. Results
Five patients with VPD and ten patients with IPD were included.
Thirteen patients fulﬁlling the criteria for VPD were excluded due to
dementia (seven patients) and/or motor deﬁcit and/or orthopedic
problems (six patients). The demographic and anthropometric
characteristics of the two groups are summarized in Table 1.
All VPD patients were males, but gender has not been described
to inﬂuence postural sway [18]. Groups did not differ in age or
anthropometric characteristics. Additionally, baseline clinical
characteristics (years of disease duration, ‘‘off state’’ MDS-UPDRS
III score, Equivalent Levodopa Daily Dose; Levodopa challenge
dose; and Motor Beneﬁt) were not signiﬁcantly different between
groups. VPD patients had a higher mPIGD score 8 [5,10], (U = 4.0;
z = 2.602; p = 0.006) due essentially to a higher score on posture
and gait. After levodopa challenge, both groups differed signiﬁ-
cantly on the MDS-UPDRS III (U = 0.0; z = 3.062; p = 0.001)) and
mPIGD score (U = 1.5; z = 2.907; p = 0.002), reﬂecting, as
expected, a lower motor beneﬁt of levodopa for patients with
VPD (U = 0.0; z = 3.067; p = 0.001).
Concerning postural sway analysis (Table 2, Fig. 1), we
observed that in both groups, the requirement for postural controlTable 1
Demographics, anthropometric and clinical variables in idiopathic Parkinson’s disease 
IPD (n = 10) 
Gender (female/male) 6/4 
Age 73 [61,79] 
Height (m) 1.61 [1.52, 1.71] 
Weight (kg) 73.2 [55, 85] 
Body Mass Index (kg/m2) 29 [24, 32] 
Center of mass (cm) 88.3 [84, 94] 
Level of Education 1 [1, 4] 
MOCA 23 [16, 30] 
Disease duration in years 6 [5, 10] 
MDS-UPDRS III Off stage 30 [16, 53] 
mPIGD off stage 3 [1, 7] 
Arising from chair 0 [0, 1] 
Gait 0 [0, 2] 
Freezing of gait 0 [0, 0] 
Postural stability 0 [0, 0] 
Posture 1 [0, 3] 
Global spontaneity of movement 2 [0, 3] 
MDS-UPDRS III On stage 13.5 [1, 24] 
mPIGD on stage 2 [0, 6] 
Arising from chair 0 [0, 1] 
Gait 0 [0, 0] 
Freezing of gait 0 [0, 0] 
Postural stability 0 [0, 0] 
Posture 1 [0, 3] 
Global spontaneity of movement 1 [0, 2] 
Levodopa equivalent daily dose 685 [300, 1532] 
Levodopa challenge dose 300 [150, 400] 
Motor beneﬁt (%) 57.5 [47, 94] 
Data is presented as median [minimum, maximum].
IPD—idiopathic Parkinson’s disease; VPD—vascular Parkinson’s disease; COM–55% of 
(mPIGD) derived from the sum of the MDS-UPDRS items (arising from chair, gait, freez
* Signiﬁcant at exact Fisher test.increased for the different tasks. This was evident in the higher
values of total sway length and distance of sway in the ML and AP
planes.
On ‘‘off state’’, in the normal stance, VPD patients had a higher
mean distance of sway (U = 7.0; z = 2.205; p = 0.028), and on the
REO task, they had a higher maximal distance (U = 8.0; z = 2.08;
p = 0.04) and higher range of anterior–posterior sway (U = 8.0;
z = 2.082; p = 0.04). In the ‘‘on state,’’ VPD patients on the REO
task also had a higher range of anterior–posterior sway (U = 5.0;
z = 2.449; p = 0.013). Of note, in the ‘‘on state,’’ there were no
signiﬁcant differences in the distance of sway between the two
groups.
In intragroup analysis of the levodopa effect, only IPD patients
had signiﬁcant changes in the normal stance task. The total length
(IPD: 6.07 [5.98, 10.81]; VPD: 1.05 [7.39, 7.39]) (z = 2.191,
p = 0.027), maximal distance (IPD: 0.65 [0.18, 2.57]; VPD:
0.14 [2.63, 1.18]) (z = 2.497, p = 0.01), range of ML (IPD:
0.63 [0.01, 2.03]; VPD: 1.19[1.18, 1.88]) (z = 2.701, p = 0.04)
and AP sway (IPD: 0.64 [0.73, 2.15]; VPD: 0.17
[5.11,1.15])(z = 1.988; p = 0.049) were signiﬁcantly increased
in only the IPD group. When analyzing the effect of visual
suppression, only IPD patients, and only in the ‘‘off state’’,
registered a signiﬁcant effect, and there was an increase in the
total length (z = 2.191, p = 0.027) and maximal distance of sway
(z = 1.988, p = 0.049). For the IPD group, there were no signiﬁcant
correlations in the basal mPIGD score (‘‘off state’’) with the change
in postural sway variables after levodopa challenge. In contrast,
VPD patients had a signiﬁcant correlation between the basal
mPIGD score (OFF state) and the total length of sway in normal
stance (rho = 0.949, p = 0.014) and range of AP sway on the REC
task (rho = 0.9, p = 0.037). The basal MDS-UPDRS-III total score
(‘‘off state’’) had no signiﬁcant correlation with any of the postural
sway variables in either group.and vascular Parkinson’s disease patients.
VPD (n = 5) Inter-group comparison
0/5 *p = 0.044
77 [63, 84] U = 18.0; z = 0.086; p = 0.418
1.61 [1.55, 1.68] U = 24.5; z = 0.062; p = 0.981
76.5 [68, 89] U = 15; z = 1.225; p = 0.254
31 [27, 34] U = 11.5; z = 1.673; p = 0.098
88 [85, 92] U = 24.5; z = 0.062; p = 0.981
1 [1, 1] x2 = 2.359; p = 0.267
12 [10, 15] U = 0.0; z = 3.067; p = 0.001
5 [3, 9] U = 25.0; z = 0.0; p = 1.0
44 [33, 57] U = 10.0; z = 1.839; p = 0.075
8 [5, 10] *U = 4.0; z = 2.602; p = 0.006
1 [0, 2] p = 0.059*
2 [1, 2] p = 0.005*
0 [0, 0] p = 1.0
0 [0, 0] p = 1.0
3 [1, 3] p = 0.067
2 [2, 3] p = 0.114
39 [26, 46] *U = 0.0; z = 3.062; p = 0.001
7 [5, 8] *U = 1.5; z = 2.907; p = 0.002
1 [0, 2] p = 0.032*
1 [1, 2] p = 0.001*
0 [0, 0] p = 1.0
0 [0, 0] p = 1.0
2 [1, 3] p = 0.121
2 [1, 3] p = 0.017*
750 [500, 1124] U = 24; z = 0.123; p = 0.931
350 [200, 400] U = 18.5; z = 0.82; p = 0.458
19 [11, 26] *U = 0.0; z = 3.067; p = 0.001
individual’s height; mPIGD—modiﬁed postural instability and gait disorder score
ing of gait, postural stability, posture, global spontaneity of movement).
Table 2
Postural kinematic variables on different postural tasks in idiopathic Parkinson’s disease and vascular Parkinson’s disease.
Kinematic variables Normal stance Romberg test with eyes open (REO) Romberg test with eyes closed (REC) REO vs.
REC off stage
REO vs.
REC on stage
Off stage On stage p-Valuea Off stage On stage p-Valuea Off stage On stagea p-Valuea p-Valuea p-Valuea
Total length of sway (cm)
IPD 13.4 [8.3, 21.1] 19.4 [12.8, 25.4] p=0.027* 21.0 [10.5, 36.8] 22.1 [8.9, 32.8] p=0.922 24 [13.8, 39.6] 23.2 [12.5, 47.2] p=0.846 p=0.027* p=0.064
VPD 13.7 [12.8, 41.2] 20.2 [10.3, 33.9] p=1.0 20.9 [18.7, 35.7] 21.3 [16.0, 50.0] p=0.31 21.8 [14.4, 38.4] 23.3 [16.2, 57.3] p=0.313 p=0.625 p=0.625
p-Valueb p=0.254 p=0.953 p=0.679 p=0.513 p=0.953 p=0.768
Maximal distance of sway (cm)
IPD 1.56 [0.92, 2.93] 2.46 [1.60, 3.55] p=0.01* 2.04 [1.36, 3.66] 2.5 [1.4, 4.3] p=0.23 2.43 [1.46, 4.70] 2.43 [1.13, 8.4] p=0.625 p=0.049* p=0.695
VPD 1.82 [1.46, 6.50] 3.0 [1.8, 4.0] p=0.81 3.7 [1.9, 9.2] 3.2 [2.0, 5.9] p=0.81 2.4 [1.64, 6.25] 3.26 [1.8, 5.4] p=0.625 p=0.188 p=0.438
p-Valueb p=0.206 p=0.440 p=0.04* p=0.129 p=0.953 p=0.594
Mean distance of sway (cm)
IPD 0.57 [0.45, 1.32] 1.03 [0.42,1.98] p=.084 1.15 [0.71, 2.04] 1.2 [0.65, 2.24] p=0.492 1.17 [0.48, 2.79] 1.22 [0.53, 4.18] p=0.432 p=0.57 p=0.77
VPD 1.15 [0.61, 2.50] 0.98 [0.5, 2.6] p=0.623 1.8 [0.78, 4.3] 1.6 [0.82, 2.5] p=0.081 1.1 [0.7, 2.3] 1.64 [0.8, 3.2] p=0.438 p=0.313 p=0.625
p-Valueb p=0.028* p=.953 p=0.129 p=0.165 p=0.679 p=0.513
Maximal linear velocity (cm/s)
IPD 0.85 [0.22, 2.78] 1.3 [0.24, 1.77] p=0.43 0.6 [0.28,2.6] 1.27 [0.37, 1.82] p=0.275 0.65 [0.43, 2.9] 1.64 [0.46, 3.72] p=0.064 p=0.275 p=0.084
VPD 0.79 [0.5, 7.20] 1.5 [0.5, 8.2] p=0.43 1.46 [0.58, 2.8] 2.2 [0.41, 5.5] p=0.188 1.48 [0.17, 3.8] 1.1 [0.06, 5.7] p=0.813 p=1.0 p=0.31
p-Valueb p=0.371 p=0.59 p=0.679 p=0.055 p=0.254 p=0.859
Range of ML sway (cm)
IPD 0.8 [0.33, 3.4] 1.82 [0.86, 3.96] p=0.004* 2.68 [1.64, 5.29] 2.03 [1.04, 5.39] p=0.275 2.49 [1.33, 5.47] 2.28 [1.23, 7.3] p=0.695 p=0.625 p=0.105
VPD 1.75 [0.67, 2.0] 2.38 [0.36, 3.63] p=0.188 2.4 [1.76, 3.20] 3.24 [2.38, 3.72] p=0.063 2.4 [1.9, 2.5] 2.4 [1.8, 5.9] p=0.625 p=1.0 p=1.0
p-Valueb p=0.165 p=0.44 p=0.679 p=0.129 p=.768 p=0.768
Range of AP sway (cm)
IPD 1.96 [0.99, 2.70] 2.86 [1.89, 3.78] p=0.049* 2.32 [1.3, 3.87] 2.45 [0.9, 4.2] p=0.77 2.24 [1.77, 3.85] 2.04 [1.30, 4.40] p=0.492 p=0.557 p=1.0
VPD 2.5 [1.6, 12.0] 2.74 [2.16, 6.9] p=0.625 4.14 [1.75, 9.96] 5.3 [2.7, 10.9] p=0.125 3.0 [1.7, 6.2] 3.3 [2.2, 7.3] p=1.0 p=0.18 p=0.063
p-Valueb p=0.371 p=0.44 p=0.04* p=0.013* p=0.371 p=0.055
Data is presented as median [minimum, maximum]. IPD—idiopathic Parkinson’s disease; VPD—vascular Parkinson’s disease; ML—medial-lateral; AP—anterior–posterior.
a Wilcoxon statistical analysis (intragroup analysis).
b Mann–Whitney statistical analysis (intergroup analysis).
* Signiﬁcant at exact Fisher test.
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Fig. 1. Displacement on x-axis (medial-lateral) and y-axis (anterior–posterior) of inertial measurement unit on center of mass (55% of Height), plotted on different conditions
(before (off) and after levodopa challenge (on)), for all subjects (idiopathic Parkinson’s disease (IPD); vascular Parkinson’s disease (VPD) patients).
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The present results indicated subclinical differences in postural
sway between VPD and AR-IPD patients. This ﬁnding is in
agreement with clinical evidence, diagnostic criteria and the
different etiopathology of these two entities [8]. In agreement with
the data from previous force platforms and IMU studies, we
also found a signiﬁcant increase in the displacement of sway from
the origin after levodopa [19]. This is relevant because the role
attributed to levodopa on postural control in IPD remains unclear
due to conﬂicting results. Herein, we also demonstrate that
levodopa only had a signiﬁcant effect on IPD but not on VPD. Sway
in patients with IPD who are in the ‘‘on state’’ are larger and faster
than when in the ‘‘off state’’, which is perhaps because levodopa
reduces the rigidity without improving control of posture or
because subclinical dyskinesia increases body motion [20]. Addi-
tionally, the decrease in sway after dopaminergic medication has
been correlated with a smaller risk of falling, whereas no change or
increased postural sway correlated with higher risk [21]. In our
study, levodopa did not have a positive effect on the range of the AP
postural sway in VPD patients. Interestingly, the main difference
between IPD and VPD was in the AP sway measures both in the
‘‘off’’ and ‘‘on’’ states. AP sway involves the inverted pendulum and
ankle muscle sway strategy of postural control, which may be less
affected in IPD than in VPD.
The etiology of the postural misalignment and ﬂexed posture in
IPD is not clear, but background muscle tone is larger, especially in
ﬂexor muscles. In spite of their forward inclination in the upright
posture, IPD patients tend to fall backwards very easily, with both
axial rigidity and poor trunk coordination contributing to the poor
stability of IPD patients in response to backward body sway
[22]. The more ﬂexed posture of VPD patients, demonstrated in
their mPIGD scores, may have contributed, but the larger AP range
of sway can also represent a distinctive variable of VPD and higher
risk of falling even without overt clinical PI.
More demanding postural control tasks, such as the Romberg
under visual suppression, may have put our patients on higher
cognitive alert and effort to control COM under stable limits. This
may have attenuated the subclinical dyskinesia and increased
postural sway that was only observed in the normal relaxed stance.
Visual suppression increases the postural instability, making the
patient more dependent on other systems, including the vestibu-
lar, proprioceptive inputs and postural controls nucleus such as thepedunculopontine nucleus [5]. We observed a signiﬁcant effect of
visual suppression on the postural sway of our IPD patients, which
is concordant with other studies on early stage IPD [19]. This
vulnerability was only present for IPD patients, which was evident
in the ‘‘off state’’ and showed a positive response to levodopa, as
previously reported [19]; importantly, we failed to ﬁnd a positive
response in VPD patients.
Increasing evidence suggests an important role of cognitive
factors, such as executive function and attention, in the control of
balance during standing and walking [23,24]. Many studies have
shown that gait in IPD is more dependent on focused attention and
external cues and that the frontal cortex may play a crucial role in
controlling gait patterns [14]. The disruption of the microstructural
organization of the frontal lobe white matter has been associated
with the severity of VPD, reinforcing the hypothesis of the frontal
lobe disconnection for gait problems and that the involvement of
ﬁbers related to the prefrontal cortex is crucial for the core features
of VPD. In this respect, we cannot exclude that some ﬁndings in VPD
patients can also be explained by their lower cognitive performance
(lower values on MoCa), albeit without the criteria of dementia.
In the absence of clinical postural instability, the higher mPIGD
score in both groups was mainly due to gait disturbance, especially
prevalent in the VPD patients. After levodopa challenge, VPD
patients had a higher basal mPIGD basal score, which is correlated
with the lower total length postural sway change in normal stance;
interestingly, this lower sway apparently persisted in the AP plane.
In most cases of VPD, gait and postural stability are simultaneously
impaired [25]. In this particular cohort of VPD patients, in the
absence of clinically assessed postural instability, gait impairment
inﬂuenced the degree of the postural sway response to levodopa.
Locomotor generators and postural control are interconnected [26],
and if postural control is still modulated by dopamine at least in the
early stages of IPD without PI, this was not evident in VPD. Unlike for
mPIGD, the UPDRS-IIII total score did not inﬂuence the postural
sway response after levodopa challenge. A pure mechanical process,
with less rigidity after levodopa inﬂuencing postural sway, is not the
sole explanation for this; central postural control circuits, both
dopaminergic and non-dopaminergic, could be involved [27].
4.1. Study limitations
It is important to note that we opted to include only the
akynetic-rigid IPD subtype and age-matched VPD patients.
M.F. Gago et al. / Gait & Posture 41 (2015) 459–464464Therefore, our methodological concerns about the purity and
homogenization of the VPD and IPD groups, excluding variables
with potential bias on postural control, such as neuromuscular,
osteoarticular and motor deﬁcits, although theoretically a strength,
led to the exclusion of a signiﬁcant number of patients encountered
in clinical practice. The small clinical sample of VPD patients limits
the statistical inferences of comparison between groups. This
difﬁculty in including a large number of VPD patients affects clinical
cross-sectional studies [28]. Our evaluation of cerebrovascular
disorder on brain MRI was merely qualitative. However, there is still
no speciﬁc abnormal structural imaging pattern for VPD [25], and
the terminology and deﬁnitions of the imaging features of cerebral
small vessel disease vary widely, although recent advances have
attempted to address this problem [29]. Nevertheless, quantitative
analysis of the impact of the cerebrovascular system on brain MRI
has been correlated with the severity of VPD [14]. Additionally, the
volume of parietal white matter lesions has been associated with the
MoCA score in VPD patients [30].
5. Conclusion
The results of our pilot study suggest that a quantitative
postural sway evaluation is a useful tool for investigating the
levodopa effect on Parkinsonian syndromes. VPD patients have
higher AP postural sway, which is correlated with the gait clinical
burden, and not responsive to levodopa. These observations
corroborate the interconnection of postural control and locomotor
networks, especially the non-dopaminergic ones.
Further studies with larger sample sizes that use less restrictive
inclusion criteria and perform multivariate analyses are needed to
determine the effect of the dopaminergic system and cognition on
postural stability. Investigation should also be extended to patients
with postural instability, monitoring the progression to more
advanced stages of IPD, different proﬁles of VPD patients and even
other Parkinsonian disorders, and a future study should include a
correlation with a quantitative gait analysis.
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